Nanjing Leads Biolabs Sets Formal Rules for Board Remuneration Committee

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) just unveiled an announcement.

Nanjing Leads Biolabs Co., Ltd. has formalized the terms of reference for its Remuneration Committee to strengthen its remuneration management mechanisms and corporate governance in line with PRC Company Law, Hong Kong Listing Rules, the Corporate Governance Code, and its Articles of Association. The new rules define the committee’s role in formulating and reviewing appraisal and remuneration plans for directors and senior management, set requirements for its composition—an odd number of members, with a majority being independent non-executive directors—and outline detailed eligibility, appointment, removal, and vacancy-filling procedures, underscoring the company’s intent to enhance transparency, independence, and regulatory compliance in board-level pay oversight.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based company listed in Hong Kong that operates under the PRC Company Law and the Hong Kong Listing Rules, indicating it is a publicly traded enterprise subject to cross-border corporate governance standards. The company has a board of directors, independent non-executive directors, and senior management positions such as general manager, deputy general manager, chief financial officer, and board secretary, reflecting a conventional listed-company governance structure, although the specific industry and product focus are not specified in this document.

Average Trading Volume: 594,245

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.63B

See more data about 9887 stock on TipRanks’ Stock Analysis page.